TRIM28 Fuels Kidney Cancer Immune Escape by Draining NAD+ and Boosting PD-L1
A newly uncovered TRIM28-PARP1 axis depletes NAD+ in tumors and T cells, enabling immune evasion in clear cell renal cell carcinoma.
Summary
Researchers identified TRIM28 as a master regulator of immune evasion in clear cell renal cell carcinoma (ccRCC). Using AI-driven gene perturbation screening and single-cell transcriptomics, they showed TRIM28 stabilizes PARP1 via SUMOylation, depleting nuclear NAD+ and activating NF-κB-driven PD-L1 expression. Simultaneously, TRIM28 reduces NAD+ availability for tumor-infiltrating CD8+ T cells, crippling their cytotoxic function. The FDA-approved drug Eltrombopag was identified as a TRIM28 inhibitor that synergizes with anti-PD-1 therapy to restore antitumor immunity in mouse models, offering a promising combination strategy for patients with ccRCC who respond poorly to current checkpoint blockade.
Detailed Summary
Clear cell renal cell carcinoma (ccRCC) is resistant to immune checkpoint blockade (ICB) despite often having CD8+ T cell infiltration—a paradox suggesting unique tumor-intrinsic immune evasion mechanisms. This study set out to identify novel molecular drivers of that resistance using a multi-layered computational and experimental approach.
The team applied Geneformer, a deep learning foundation model, to single-cell RNA sequencing data from ccRCC patients (GEO: GSE159115), conducting in silico knockout of 11,403 genes in malignant epithelial cells. TRIM28 emerged as a top hit: its simulated loss shifted tumor cells toward a normal epithelial transcriptional state. Clinical validation across TCGA, ICGC, and GSE36895 cohorts confirmed TRIM28 is significantly overexpressed in ccRCC tumors, correlates with higher tumor stage, nodal and distant metastasis, and predicts poor overall survival.
Mechanistically, TRIM28 functions as a SUMO E3 ligase for PARP1, a major NAD+-consuming nuclear enzyme. TRIM28-mediated SUMOylation stabilizes PARP1 by blocking its ubiquitin-proteasome degradation and promotes its nuclear retention. This selectively depletes nuclear NAD+ without affecting cytoplasmic pools—a compartment-specific metabolic reprogramming. Reduced nuclear NAD+ inhibits SIRT1 deacetylase activity, leading to hyperacetylation and activation of NF-κB p65, which transcriptionally upregulates PD-L1. Chromatin immunoprecipitation confirmed p65 binding to the PD-L1 promoter under these conditions.
Beyond tumor-intrinsic effects, TRIM28 also impairs CD8+ T cell function by reducing extracellular and intratumoral NAD+ availability. Metabolic profiling showed that CD8+ T cells co-cultured with TRIM28-high tumor cells had suppressed mitochondrial respiration and reduced effector cytokine production. Restoring NAD+ via NMN supplementation partially rescued T cell function, validating the metabolic mechanism.
For therapeutic translation, virtual screening identified Eltrombopag—an FDA-approved thrombopoietin receptor agonist—as a small-molecule TRIM28 inhibitor. In murine ccRCC models including patient-derived xenografts, Eltrombopag combined with anti-PD-1 antibody significantly reduced tumor growth, restored intratumoral NAD+ levels, decreased PD-L1 expression, and enhanced CD8+ T cell cytotoxicity compared with either agent alone. These results establish a novel TRIM28/PARP1/NAD+/PD-L1 immunometabolic axis and position Eltrombopag as a repurposable candidate for combination immunotherapy in ccRCC.
Key Findings
- TRIM28 SUMOylates PARP1 to stabilize it, causing nuclear NAD+ depletion that activates NF-κB p65 and upregulates PD-L1.
- TRIM28 depletes NAD+ in the tumor microenvironment, directly impairing CD8+ T cell respiration and cytotoxic killing.
- High TRIM28 expression correlates with advanced tumor stage, metastasis, and poor survival in multiple ccRCC cohorts.
- Eltrombopag identified as a TRIM28 inhibitor that synergizes with anti-PD-1 to suppress tumor growth in mouse models.
- AI-based Geneformer screening of 11,403 genes pinpointed TRIM28 as a key driver of malignant epithelial cell identity in ccRCC.
Methodology
The study combined Geneformer-based in silico gene perturbation screening of single-cell RNA-seq data with functional validation in shRNA knockdown and overexpression ccRCC cell models, patient-derived xenografts, co-immunoprecipitation, chromatin immunoprecipitation, RNA-seq, mass spectrometry, and metabolomics. In vivo efficacy of Eltrombopag plus anti-PD-1 was assessed in syngeneic murine tumor models.
Study Limitations
All in vivo combination therapy experiments were conducted in murine models; human clinical validation is absent. The specificity of Eltrombopag for TRIM28 versus other targets requires further pharmacological characterization. The study focuses on ccRCC and it is unclear whether findings generalize to other renal or solid tumor subtypes.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.